glp-1 obesity drug news today october 16 2025 Drugmakers are racing to find the next Wegovy. These trials are ones to watch How Supply and Demand for
Description
In this review, we showed that GLP-1 receptor agonists can effectively change cognitive function, BMI and blood glucose levels in patients with AD
In ConclusionEmpowering Midlife Health Through Blood Sugar and GLP-1 Support Managing blood sugar and supporting GLP-1 production is essential for healthy aging
Seven cardiovascular outcomes trials have been performed in the past 4 years, all of which found non-inferiority for cardiovascular outcomes, with many finding superiority of these drugs
Liraglutide treatment may affect renin and aldosterone release
This is promising data that supports the need for further studies evaluating whether GLP-1 receptor antagonists can reduce risk in this population at high risk for developing cancer. 1 What are next steps for GLP-1 research in this population
Using his RIA he was able to show that in the fasting state glucagon gets released in addition to insulin to raise plasma glucose
